SCHEMBL3563199

SCHEMBL3563199

CCCc1ccccc1-c1ccccc1[O]

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 1/20 0.38
NR1H2 P55055 1/20 0.37
NR1H3 Q13133 1/20 0.37
ELANE P08246 2/20 0.35
CTSG P08311 1/20 0.35
CTSL P07711 1/20 0.35
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
CYP2D6 P10635 1/20 0.34
CSNK2A2 P19784 1/20 0.34
CSNK2B P67870 1/20 0.34
CSNK2A1 P68400 1/20 0.34
CSNK2A3 Q8NEV1 1/20 0.34
DAO P14920 1/20 0.33
SOAT1 P35610 1/20 0.33
LIPG Q9Y5X9 1/20 0.32
MAPT P10636 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
GABRA1 P14867 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6704515 0.87 PPARA (0.41) PPARANR1H2NR1H3ELANECTSG
SCHEMBL16166663 0.86 NR1H2 (0.51) PPARANR1H2NR1H3LIPG
SCHEMBL3563147 0.85 CSNK2A2 (0.44) CYP2D6CSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL186669 0.82 GABRA1 (0.37) PPARAELANEDAOLIPGMAPT
SCHEMBL3569673 0.82 PPARA (0.38) PPARANR1H2NR1H3ELANECTSG
SCHEMBL5545176 0.75 GABRA1 (0.37) ELANEDAOGABRA1GABRB2
SCHEMBL13685146 0.75 DPP4 (0.47) PPARA
SCHEMBL982272 0.75 HTR1A (0.47) PPARAELANECTSGCYP2D6
SCHEMBL4527020 0.75 KDM4E (0.38) PPARANR1H2NR1H3ELANECTSG
SCHEMBL2494545 0.75 PPARA (0.35) PPARANR1H2NR1H3ELANECTSG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1653960-A4 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC (US) 2008-11-26 EP claimed
EP-1653960-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC. (US) 2006-05-10 EP claimed
US-20050215526-A1 Melanin concentrating hormone receptor antagonist AMGEN, INC. 2005-09-29 US claimed
WO-2005019167-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN, INC. (US) 2005-03-03 WO claimed
WO-2013077943-A1 CATALYST COMPOUNDS AND USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-05-30 WO disclosed
US-7659276-B2 Melanin concentrating hormone receptor antagonist AMGEN, INC. (US) 2010-02-09 US disclosed
US-20090143405-A1 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN, INC. (US) 2009-06-04 US disclosed
US-7514438-B2 Melanin concentrating hormone receptor antagonist AMGEN, INC. (US) 2009-04-07 US disclosed
EP-1653960-A4 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC (US) 2008-11-26 EP disclosed
EP-1653960-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN INC. (US) 2006-05-10 EP disclosed
US-20050215526-A1 Melanin concentrating hormone receptor antagonist AMGEN, INC. 2005-09-29 US disclosed
WO-2005019167-A2 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST AMGEN, INC. (US) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143405-A1 MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST MCHR1, MC1R, NPY1R PPARA 3423/4885NR1H2 320/4885NR1H3 382/4885
US-20050215526-A1 Melanin concentrating hormone receptor antagonist MCHR1, MC1R, NPY1R PPARA 3423/4885NR1H2 320/4885NR1H3 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.